Let’s start with the Oil Service sector chart: $OIH, shall we?

The above is a weekly chart.  One quick look and you know it is on a strong uptrend.

Fundamentally speaking, there are strong demand for oil service in the coming future.  Do you know why?

The Permian Basin region

Believe it or not, the ongoing speculation is that the Permian Basin has the potential to be the world second largest oil field behind Saudi Arabia.  This speculation is also my reason in owning $PXD.

With that kind of oil reserve underneath, oil service industry is going to be quite busy, don’t you think?

Personally, I like to trade $WG.

Take a look at the weekly chart below:

While there are zig-zag on the price movement, the general direction is still up. Recent correction from earnings report provided the “zag”/correction for me to buy in for the ride.

Today, $WG bounces off the daily 5 MA and takes out the high of the last five days; this is good enough for me to start a position.

If price can close above the 79 & 89 MA lines today, it will be further confirmation that $WG can rebounce from here and move on higher through out 2014.

My 2 cents.

Comments »

Here we go again, my x number of times to catch the bottom of $NUGT.  I had a good run back in August and a few attempts afterward that didn’t quite work out.  Now I’m trying again for the $100 roll by getting back in yesterday.

Today is a good sign that $NUGT may be getting ready to run hard.   With a strong gap-up and a persistent momentum that hasn’t shown any weariness yet, the odd of $100 roll is increasing.

Take a look at the daily chart:

The 5 SMA has finally crossed over the 15 SMA today and a solid green bar even after the gap-up.  I like to see price action takes out the upper Bollinger band to show proof of strength.  There are two overhead resistances however- the 79 SMA and the 89 XMA.  In due time, both of these resistances may be turning up in direction as well.  If that is the case, the resistances may be weakened for $NUGT to pierce thru.

Now take a look at the hourly chart:

Did you see the cup and handle breakout?  Statistically speaking, I’ve made more money trading cup & handle breakout than other methods.  This strong break out bode well for $NUGT today.

My 2 cents.

Comments »

Why not?

Kingold Jewelry, Inc. ($KGJI) engages in the design, manufacture, and sale of gold jewelry, ornaments, and investment-oriented products in the People’s Republic of China (the PRC). It provides a range of gold products, including gold necklaces, rings, earrings, bracelets, pendants, and gold bars. The company sells its products under the Kingold brand name directly to retailers, distributors, and wholesalers covering 25 provinces and municipalities in the PRC. Kingold Jewelry, Inc. was founded in 2002 and is headquartered in Wuhan, the People’s Republic of China.

Although I am late to the party, I don’t think the run is over yet.

Take a look at the daily chart:

Yesterday, price had a correction to the downside but was stopped by the support of the daily 5 SMA.  With the 15 SMA right below the 5 SMA and both are still heading upward in direction, I took today as an opportunity to initiate position looking for trend continuation.

Take a look at the weekly chart:

Price action has taken out both the 79 SMA and the 89 XMA with the 5 and 15 SMAs pointing upward.  There may be a long-term bull run here.

My 2 cents.

Comments »

I took this $CALL because it broke out of the consolidation range last Friday.  I bought a starter position after it took out the opening range and then added after it was able to maintain above the opening range.

Take a look at the daily chart below:

While Friday was an up day for $CALL, the pause here would be that the price action was hitting against the 79SMA and 89XMA at Friday close.  Noticed that both the 79 and 89 were lumped together on this resistance.  If price action could take out this double MAs resistance, price could rally hard since this one got a high short interest per Yahoo Finance:

Shares Short (as of Sep 30, 2013)3:	4.18M
Short Ratio (as of Sep 30, 2013)3:	22.20
Short % of Float (as of Sep 30, 2013)3:	26.60%

Below is the weekly chart:

Did you see how the weekly price is bouncing off the long-term support line?  Currently, even the weekly chart has a 15 SMA resistance against current price.  So, there exist a possible failure in the rally due to the weekly and daily resistances.  On the other hand, a breakout of these two time-frames resistance could mean a continued rally.

Fundamentally speaking, I use MagicJack myself so I know the benefit directly. I used to have Verizon land-line and the monthly charge to me was an average of $30+ per month.  Now,I pay less than $50 per year!  On top of that, I’ve the benefit of using the land-line number on my Android mobile phone by installing the MagicJack APP so that I can take or make call on my mobile phone on the go.

The convenience and the saving of of having MagicJack is fantastic to me; so I have to assume it applies to whomever use the service as well.  I can see there are other competition to MagicJack but I only know what I’m using.

Anyway, MagicJack expansion to oversees may be the next catalyst for the price rally.

In summary, it depends on how price action behave the coming week against the weekly and daily MAs resistances; if it break out higher, I may add more; and if it fails, I will probably bail out for small losses or small gain.

My 2 cents

 

Comments »

Folks, we are heading into Oct 16th FDA advisory committee meeting.  Place your chips either at the center of the table or put it back into your pocket.  As for myself, I moved a sizable amount into the center.

Well, what cards do I have that I’m willing to risk such amount on this $AMRN bet?  you may wonder.

Here are my cards:

I’ve been taking Vascepa everyday (4 grams a day) since March.  Although I was fearful of the large size of the capsule in the beginning, now I’m looking forward to taking them at meal time.  Believe me when I said it is actually my body that looks forward to taking Vascepa.  Despite its large size, I swallowed the pill as if it was nothing.  It went down my throat smoothly with no reflex of gagging as some might have feared.  I can see that $AMRN is using the best quality capsule to contain the EPA ingredient inside which make it so much easier to swallow.  I had swallowed over-the-counter (OTC) fish oil capsules before and I can tell you the quality of the capsule used by Vascepa is far superior.

Why would my body looked forward to taking the capsules?  I believe because the EPA ingredient in Vascepa is doing something good inside my body.  So far, I’ve no side-effect whatsoever from the months of taking Vascepa.  My latest blood test from my doctor has reflected significant improvement on my trig level.  And I’m feeling fine where my heart is concerned.

Is it psychological that I’m looking forward to taking Vascepa or is it really my body who craves it?  Does it really matter?  When you think about this, you know I will always get my refill.  Imagine all the other people who is taking Vascepa or is going to be taking Vascepa feel the same way that I’m feeling.  Go figure.

Next, why will FDA Advisory committee meeting have anything against a specialized fish-oil with high concentration of EPA that can provide the benefits that over-the-counter fish oil cannot?  Think about this, by taking a favorite stance on Vascepa on the Anchor indication, FDA may be encouraging people to stay away from the OTC fish oils with questionable purity and go for the healthier fish-oil that have been proven in Phase 3 trials with multitude of benefits.

Have you been to Costco lately?  If you wander into the aisle where the Omega-3 fish oils are stocked, you will be surprised how many different brands of Omega-3 are available.  In other words, there are huge demand for Omega-3 fish oil.   Offer these people a prescription grade Omega-3 fish oil with proven benefits and how many do you think will jump over from OTC brands?

There you have it, my fundamental reason for believing $AMRN’s Vascepa will get a nod from the FDA Advisory committee.  If it is good for the population, why withhold it?  It is my opinion that there is simply no risk for the FDA Advisory committee to clear the road for Vascepa.

Now, take a look at the daily chart:

Currently, from the daily chart, price action has cleared all the MAs (5, 15, 79, and 89).  Price action has obviously taken a positive turn and is on the way to take out the recent high at $7.40.

Now, take a look at the weekly chart:

As you can see, the downtrend line has been broken. Price action has taken out the 5 and 15 SMA lines.  There are two overhead resistances from the 79SMA and 89XMA.  With any good news from the FDA, these two resistances will be taken out quite effectively.

Now, stand back and look at both of the charts again, the daily and the weekly.  Did you see the cup and handle pattern being developed?  Does it look like a break out is about to take place?

Am I crazy to bet big on $AMRN?  Maybe I am; but what is the point of not betting big when I “personally” perceive a statistically advantage here?  After all, isn’t why we “speculate” in the stock market?  Searching for a stock with a probability of making a run to the upside?  To me, it is a calculated risk I’m willing to take.

But don’t forget, I’ve been wrong and have taken big losses before; on the other hands, I’ve also made a few successful bets as well.

My 2 cents.

Comments »

I like $GALE.  Besides the potential disruptive biotechnology that can eradicate breast cancer, it is launching the sales of ABSTRAL® (fentanyl) sublingual tablets which are indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Basically, while we are waiting for the development of their breast cancer treatment to come to fruition, they have the mean to start generating revenues from the specialized painkiller.  This is the kind of painkiller that will provide faster pain relief than the usual opiate drug such as morphine.

I was lucky to sell before the secondary offering and then giving the opportunity to buy them back after the secondary offering.

Sidebar: I’ve learned to take advantage of the opportunity of a dip provided by secondary offering.  If the company has a solid fundamental, secondary offering is an “offering” of an opportunity for investors to either add or buy at a discount.  I had been waiting for a chance to get back on the 3D printer and $SSYS gave me the opportunity with a secondary offering.

Now, I’m waiting for the fundamental to take effect to drive the $GALE back up based on the future revenues of Abstral or the possibility of a take-over.

Take a look at the daily chart below:

There is a breakout to the upside today from the consolidation after the secondary offering.  This signifies that the momentum is still bullish despite a gap-down.  There may be some resistance from here due to the overhang of the 79SAM and 89XMA.  If price can take out these two MAs, then we are heading up.

Take a look at the weekly chart below:

Did you see that the uptrend is still intact?  Did you see the price is bouncing off the 79SMA and 89XMA?  This bounce off is more significant than the short-term daily 79SMA and 89XMA resistance I mentioned earlier from the daily chart.

Now, you know why $GALE should be your best friend, eh?

My 2 cents

 

 

Comments »

When I found out that $TTWO’s new Grand Theft Auto V (GTAV) game raked in over $1 billions in three days after launching, I was pleasantly surprise to see price actually softened instead of a spike up.  I was pleased because I didn’t have to chase the stock to buy it.

Take a look at the daily chart below:

Did you see how price kept bouncing off the 79SMA as well as the 89XMA?  When both 79SMA and 89XMA are coming close to each other, the support is even more effective per my observation. 

I was able to buy some at low $17.xx before people start to take notice that the revenues stream from GTAV has ONLY just begun (my opinion only of course).  There are still money coming in for the computer PC version that has yet to launch.  There are about 136 million units of current consoles of XBox 360 (59.4 million) and Playstation 3 (77 million) out there with only a little over 12% of these console owners who have already bought the GTAV (based on $1 billion dollars sales divided by $59.99 retail price).  With word-of-mouth going on how great the game is, I’m betting another 7-8% of the uncommitted console owners will eventually buy the game between now and X’mas time.

I’m not so sure about the sales on the new consoles XBox One and Playstation 4 since $TTWO’s Rockstar has not announced any plans to develop the game to support the new consoles.  But the lack of sales on these new consoles can be made up by the revenues stream from the online version of GTAV which will be launching in October.

Take a look at the monthly chart below:

From the monthly chart, you can see that there is a breakout from May 2011 high.  Remember, the longer the time-frame (monthly in this case), the more prominent is the breakout.

Can $TTWO restores its former glory by retaking $27.95 achieved back in 2008?  If the money keeps on dropping by $TTWO door with continuing sales of GTAV, I believe it can.

In other words, selling on news may be premature due to $TTWO surprisingly strong sales on its new GTAV game.

My 2 cents.

 

Comments »

I’ve been accumulating $CERS again recently after a rough start earlier in the year.  This time, I think I will just hold it for the fundamental reason that, in my opinion, the services offer by $CERS’ products may become a standard requirement for all blood banks in the future.

Why not?

As our population grows, it increases the need for more blood in the blood banks.  By utilizing $CERS products, blood banks can eliminate the risk of contaminated blood.

It is this simple.

European countries are already using $CERS’ products.  Cerus is now waiting for FDA to approve the use of its product in the US.  What is the odd of FDA disapproving it when the products have already been in use by other countries?

In summary, there is a large market in the US for Cerus to tap into once FDA gives its nod.  Thus, the risk in this play is really the decision of the FDA.  Oh wait, this is nothing new here in the land of biotech…

But then I’m willing to wager that the FDA approval of Cerus product is as “fill in the blank” as approving $AMRN for their mid-trig (200-500) level use.

Now you see why I’m betting on this one, eh?

Take a look at the monthly chart below.  I like to see the $10 target reach in the early 2014 if not sooner.

Today price action took out $6 resistance; naturally, I added a bit more because of this breakout.

My 2 cents.

Below is information from $CERS website on how its product works:

How INTERCEPT Works

The INTERCEPT Blood System for platelets and plasma employs the unique properties of our amotosalen HCl molecule to block the replication of DNA and RNA, preventing the proliferation of susceptible pathogens. For red blood cell pathogen inactivation, a similar treatment process has been developed using a different molecule called S-303.

Platelets and red blood cells are not inactivated by the crosslinking process because they do not require nucleic acids to function.  Plasma is not inactivated by the treatment because it is an acellular product (proteins and liquid).

Controlled Reaction
The interactions of amotosalen and S-303 with DNA and RNA are highly specific and occur with high frequency even at low concentrations of nucleic acids (Fig.1).  Once inside a pathogen, the compounds dock in between the nucleic acid base pairs.  Upon illumination with ultraviolet A light (amotosalen) or a change in pH (S-303), an interstrand crosslink is formed, “locking” the DNA or RNA together so that it can no longer replicate.  These reactions require UVA light or pH change, and will not continue in the absence of these conditions.

 Figure 1 

Broad Spectrum of Inactivation
The crosslinking activity of amotosalen and S-303 is not limited to particular nucleic acid sequences or specific families of pathogens, so unlike testing procedures this blood safety method does not rely upon advance identification of potentially harmful organisms. The replication of a broad spectrum of viruses, bacteria and parasites, as well as leukocytes, can be inactivated with these treatment processes.

– See more at: http://www.cerus.com/Products/how-intercept-works2/default.aspx#sthash.66Z5KwFt.dpuf

Comments »

Yes, I bought a boat load of this calls this morning.  Here are my reasons:

1. – On September 17th, the Chinese Ministry of Finance announced the long anticipated renewal of China’s New Energy Vehicle (i.e. electric vehicle or EV) subsidies.
2. – China’s first car-sharing scheme starts in Hangzhou
3. – JINHUA, China, Aug. 9, 2013 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the ‘Company’ or ‘Kandi’) (Nasdaq:KNDI), today announced that the construction of pure EV smart vertical parking and charging facilities for public EV sharing system (the ‘Project’) is right on schedule. According to the updated progress report, there will be five pure EV smart vertical parking and charging facilities completed in the coming September. By the end of 2013, 30-40 pure EV smart vertical parking and charging facilities are expected to be built in Hangzhou City. In a year from now, 5,000 to 10,000 Kandi pure EV ‘JNJ6290EV’ model and Kandi-Geely co-developed Brand ‘JL7001BEV’ will be deployed in Hangzhou City based on the progress.
4. – The pilot project for Public EV sharing project is very well received by Jinshan District of Shanghai and the local government is in the process of the location selection. The trial operation of Shanghai’s public EV sharing system is expected to be launched before the end of 2013.

Notice that on point 3 and point 4, if business is progressing as planned which I’m betting that it will, $7.50 will be easily taken out before December comes around.

Chartwise, the daily chart looks like a cup & handle breakout is about to happen as soon as the $5.72 high is taking out.

Of course, this is a highly speculative play where if there is no progress in the business development per above, you can lose all your option premium.

My 2 cents.

Comments »

Take a look at the daily chart below.

Can you see the “triple-bottom” with a slight angle to the upside on the trendline?  This triple-bottoms can only be confirmed if price does not penetrate the low of Sept 13th.  For me, this represents a low risk trade.  I bought a starter position today with a GTC hard stop below the Sept 13th low.  Let’s see if I can hit the ball over the park “again” this time.

My 2 cents

Comments »